Avixgen Inc.

8 patents currently held · Updated Nov 14, 2026

Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Ending by 2030

Jan 2028

Next term end

When these terms end

5 yrs10 yrs20 yrs

Held patents by the year their term ends

20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.

1 fee due Jan 18, 2027
The maintenance fee for Angiogenesis-inhibiting peptide and composition for preventing and treating angiogenesis-related disease comprising same as active ingredient (US 11,702,449) comes due Jan 18, 2027. Unpaid by Jul 19, 2027, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.

Showing 1 to 8 of 8

Patent	Title	Status	Expires	Confidence
US 9,738,905	Vector for expressing NC protein of HIV and method for producing NC protein using the same In force Term ends Jan 4, 2028 · From the USPTO record	In force	Term ends Jan 4, 2028	From the USPTO record
US 10,149,888	Method of inhibiting HIV replication utilizing the P7 nucleocapsid protein In force Term ends Feb 13, 2028 · From the USPTO record	In force	Term ends Feb 13, 2028	From the USPTO record
US 10,231,971	Pharmaceutical Composition for Preventing and Treating Dry Eye Diseases, Containing Imatinib as Active Ingredient In force Term ends Jun 22, 2036 · High confidence	In force	Term ends Jun 22, 2036	High confidence
US 11,040,999	Angiogenesis-inhibiting peptide and composition for preventing and treating angiogenesis-related disease comprising same as active ingredient In force Ends no later than Jul 5, 2036 · From the USPTO record	In force	Ends no later than Jul 5, 2036	From the USPTO record
US 11,702,449	Angiogenesis-inhibiting peptide and composition for preventing and treating angiogenesis-related disease comprising same as active ingredient In force Ends no later than Jul 5, 2036 · From the USPTO record	In force	Ends no later than Jul 5, 2036	From the USPTO record
US 9,969,771	Tetrapeptide having effect of inhibiting VEGF-induced angiogenesis and use thereof In force Term ends Jul 28, 2036 · From the USPTO record	In force	Term ends Jul 28, 2036	From the USPTO record
US 11,208,433	Peptide for inhibiting skin inflammation and composition for preventing or treating skin inflammation containing the same In force Term ends Dec 17, 2038 · From the USPTO record	In force	Term ends Dec 17, 2038	From the USPTO record
US 11,547,649	Fusion protein bound to cell-permeable peptide, and composition comprising fusion protein or cell-permeable peptide and epithelial cell growth factor as active ingredients In force Term ends Jun 7, 2039 · From the USPTO record	In force	Term ends Jun 7, 2039	From the USPTO record

Also on record, not counted in the 8: 3 lapsed for an unpaid fee. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built

Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Export every term end as CSV · Pro

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

6 no status recorded

List them